586 related articles for article (PubMed ID: 26395836)
21. Equivalence and switching between biosimilars and reference molecules in rheumatoid arthritis: protocol for a systematic review and meta-analysis.
Ascef BO; Almeida MO; de Medeiros Ribeiro AC; Andrade DCO; de Oliveira Júnior HA; Pereira TV; de Soárez PC
Syst Rev; 2021 Jul; 10(1):205. PubMed ID: 34274019
[TBL] [Abstract][Full Text] [Related]
22. Therapeutic Equivalence of Biosimilar and Reference Biologic Drugs in Rheumatoid Arthritis: A Systematic Review and Meta-analysis.
Ascef BO; Almeida MO; Medeiros-Ribeiro AC; Oliveira de Andrade DC; Oliveira Junior HA; de Soárez PC
JAMA Netw Open; 2023 May; 6(5):e2315872. PubMed ID: 37234004
[TBL] [Abstract][Full Text] [Related]
23. Biosimilars for the Management of Inflammatory Bowel Diseases: Economic Considerations.
Gulacsi L; Pentek M; Rencz F; Brodszky V; Baji P; Vegh Z; Gecse KB; Danese S; Peyrin-Biroulet L; Lakatos PL
Curr Med Chem; 2019; 26(2):259-269. PubMed ID: 28393687
[TBL] [Abstract][Full Text] [Related]
24. Retention Rate and Safety of Biosimilar CT-P13 in Rheumatoid Arthritis: Data from the Korean College of Rheumatology Biologics Registry.
Kim HA; Lee E; Lee SK; Park YB; Lee YN; Kang HJ; Shin K
BioDrugs; 2020 Feb; 34(1):89-98. PubMed ID: 31734899
[TBL] [Abstract][Full Text] [Related]
25. Treatment of moderate rheumatoid arthritis with different strategies in a health resource-limited setting: a cost-effectiveness analysis in the era of biosimilars.
Wu B; Song Y; Leng L; Bucala R; Lu LJ
Clin Exp Rheumatol; 2015; 33(1):20-6. PubMed ID: 25438197
[TBL] [Abstract][Full Text] [Related]
26. A review on biosimilar infliximab, CT-P13, in the treatment of inflammatory bowel disease.
Farkas K; Molnár T
Immunotherapy; 2018 Feb; 10(2):107-117. PubMed ID: 29124994
[TBL] [Abstract][Full Text] [Related]
27. Biosimilar infliximab for inflammatory bowel disease: from concepts to clinical practice. Case study illustrated with CT-P13.
Schreiber S; Panés J; Kwon B; Hong S; Peyrin-Biroulet L
Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():5-15. PubMed ID: 26395530
[TBL] [Abstract][Full Text] [Related]
28. Switching to biosimilar infliximab (CT-P13): Evidence of clinical safety, effectiveness and impact on public health.
Braun J; Kudrin A
Biologicals; 2016 Jul; 44(4):257-266. PubMed ID: 27117857
[TBL] [Abstract][Full Text] [Related]
29. Budget Impact of Sequential Treatment with Biologics, Biosimilars, and Targeted Synthetic Disease-Modifying Antirheumatic Drugs in Thai Patients with Rheumatoid Arthritis.
Osiri M; Dilokthornsakul P; Chokboonpium S; Suthipinijtham P; Koolvisoot A
Adv Ther; 2021 Sep; 38(9):4885-4899. PubMed ID: 34370276
[TBL] [Abstract][Full Text] [Related]
30. The safety of emerging biosimilar drugs for the treatment of rheumatoid arthritis.
Braun J; Kay J
Expert Opin Drug Saf; 2017 Mar; 16(3):289-302. PubMed ID: 28068848
[TBL] [Abstract][Full Text] [Related]
31. Ten years of publicly funded biological disease-modifying antirheumatic drugs in Australia.
Hopkins AM; Proudman SM; Vitry AI; Sorich MJ; Cleland LG; Wiese MD
Med J Aust; 2016 Feb; 204(2):64-8. PubMed ID: 26821102
[TBL] [Abstract][Full Text] [Related]
32. Biosimilar Monoclonal Antibodies for Inflammatory Bowel Disease: Current Comfort and Future Prospects.
Gecse KB; Lakatos PL
Drugs; 2016 Oct; 76(15):1413-1420. PubMed ID: 27638739
[TBL] [Abstract][Full Text] [Related]
33. A review of the literature analyzing benefits and concerns of infliximab biosimilar CT-P13 for the treatment of rheumatologic diseases: focus on interchangeability.
Becciolini A; Raimondo MG; Crotti C; Agape E; Biggioggero M; Favalli EG
Drug Des Devel Ther; 2017; 11():1969-1978. PubMed ID: 28721016
[TBL] [Abstract][Full Text] [Related]
34. A 5-year Retrospective Analysis of Drug Survival, Safety, and Effectiveness of the Infliximab Biosimilar CT-P13 in Patients with Rheumatoid Arthritis and Ankylosing Spondylitis.
Kim TH; Lee SS; Park W; Song YW; Suh CH; Kim S; Lee YN; Yoo DH
Clin Drug Investig; 2020 Jun; 40(6):541-553. PubMed ID: 32328979
[TBL] [Abstract][Full Text] [Related]
35. Characteristics and outcomes of rheumatoid arthritis patients who started biosimilar infliximab.
Sung YK; Cho SK; Kim D; Won S; Choi CB; Bang SY; Hong SJ; Kim HA; Koh EM; Lee HS; Suh CH; Yoo DH; Bae SC
Rheumatol Int; 2017 Jun; 37(6):1007-1014. PubMed ID: 28214924
[TBL] [Abstract][Full Text] [Related]
36. Subsequent entry biologics/biosimilars: a viewpoint from Canada.
Russell AS; Ahluwalla V; Barnabe C; Jamal S; Offer RC; Olszynski WP; Shojania K; Haraoui B
Clin Rheumatol; 2012 Sep; 31(9):1289-92. PubMed ID: 22923182
[TBL] [Abstract][Full Text] [Related]
37. Biosimilars in Dermatology: Current Situation (Part II).
Puig L; Carretero G; Daudén E; Ferrándiz C; Marrón SE; Martorell A; Pérez-Suárez B; Rodriguez-Cerdeira C; Ruiz-Villaverde R; Sánchez-Carazo JL; Velasco M;
Actas Dermosifiliogr; 2015 Sep; 106(7):550-4. PubMed ID: 26049964
[TBL] [Abstract][Full Text] [Related]
38. Long-term efficacy and cost-effectiveness of infliximab as first-line treatment in rheumatoid arthritis: systematic review and meta-analysis.
Zrubka Z; Gulácsi L; Brodszky V; Rencz F; Alten R; Szekanecz Z; Péntek M
Expert Rev Pharmacoecon Outcomes Res; 2019 Oct; 19(5):537-549. PubMed ID: 31340686
[No Abstract] [Full Text] [Related]
39. [Evolution of biologicals in inflammation medicine--biosimilars in gastroenterology, rheumatology and dermatology].
Schreiber S; Luger T; Mittendorf T; Mrowietz U; Müller-Ladner U; Schröder J; Stallmach A; Bokemeyer B
Dtsch Med Wochenschr; 2014 Nov; 139(47):2399-404. PubMed ID: 25390629
[TBL] [Abstract][Full Text] [Related]
40. The Rituximab Biosimilar CT-P10 in Rheumatology and Cancer: A Budget Impact Analysis in 28 European Countries.
Gulácsi L; Brodszky V; Baji P; Rencz F; Péntek M
Adv Ther; 2017 May; 34(5):1128-1144. PubMed ID: 28397080
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
